Oppenheimer analyst Jay Olson lowered the firm’s price target on Enanta (ENTA) to $14 from $16 and keeps an Outperform rating on the shares. The firm notes the company reported Q4 results with quarterly HCV royalties of $14.6M, OpEx of $44.5M, and $248.2M cash expected to provide runway into 2027. Enanta remains on track to report topline results from Phase 2 RSVPEDs study of zelicapavir in infants and children with RSV in December.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA: